Ulipristal Acetate Gedeon Richter Unión Europea - esloveno - EMA (European Medicines Agency)

ulipristal acetate gedeon richter

gedeon richter plc. - ulipristal acetat - leiomyoma - spolni hormoni in zdravila genitalni sistem, - ulipristal acetata, ki je navedena za eno zdravljenje, seveda pre-operative zdravljenje zmerne do hude simptome maternice fibroids v odrasle ženske v rodni dobi. ulipristal acetata je primerna za občasno zdravljenje zmerne do hude simptome maternice fibroids v izobraževanje žensk v rodni dobi, ki niso primerni za operacijo.

Abevmy Unión Europea - esloveno - EMA (European Medicines Agency)

abevmy

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. za nadaljnje informacije o statusu her2 glejte poglavje 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Magnevist 0,5 mmol/ml raztopina za injiciranje v napolnjeni injekcijski brizgi Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v napolnjeni injekcijski brizgi

bayer pharma ag - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Magnevist 0,5 mmol/ml raztopina za injiciranje v steklenici Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v steklenici

bayer pharma ag - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Magnevist 0,5 mmol/ml raztopina za injiciranje v viali Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v viali

bayer d.o.o. - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Magnevist 0,5 mmol/ml raztopina za injiciranje v viali Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v viali

bayer d.o.o. - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Magnevist 0,5 mmol/ml raztopina za injiciranje v viali Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v viali

bayer pharma ag - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Magnevist 0,5 mmol/ml raztopina za injiciranje v viali Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

magnevist 0,5 mmol/ml raztopina za injiciranje v viali

bayer pharma ag - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Emtricitabine/Tenofovir disoproxil Zentiva Unión Europea - esloveno - EMA (European Medicines Agency)

emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - emtricitabin, tenofovirdizoproksil fosfat - okužbe z virusom hiv - antivirusi za sistemsko uporabo - zdravljenje okužbe z virusom hiv-1 infectionemtricitabine/tenofovir disoproxil zentiva je navedeno v protiretrovirusnimi kombinacija terapijo za zdravljenje okužbe z virusom hiv-1 okuženih odraslih. emtricitabine/tenofovir disoproxil zentiva je tudi navedeno, za zdravljenje okužbe z virusom hiv-1 okuženih mladostniki, z nrti odpornost ali toxicities nasprotuje uporabi prvo vrstico agenti. pre-izpostavljenost profilakso (prep)emtricitabine/tenofovir disoproxil zentiva je navedeno v kombinaciji z varnejše spolnosti prakse za pre-izpostavljenost preventivo za zmanjšanje tveganja za spolno pridobljenih z virusom hiv-1 okužbe pri odraslih in mladostnikih, ki imajo visoko tveganje.

Emtriva Unión Europea - esloveno - EMA (European Medicines Agency)

emtriva

gilead sciences ireland uc - emtricitabin - okužbe z virusom hiv - antivirusi za sistemsko uporabo - emtriva je indicirana za zdravljenje odraslih in otrok, okuženih s hiv-1 v kombinaciji z drugimi protiretrovirusnimi zdravili. ta navedba temelji na študijah, v zdravljenje-naivnih bolnikov in zdravljenje-izkušeni bolniki s stabilno virological nadzor. ni izkušenj z uporabo emtriva pri bolnikih, ki ne morejo sedanji režim ali ki je ni več regimens. pri odločanju o novi režim za bolnike, ki so neuspešne protiretrovirusnimi režim, paziti je treba upoštevati vzorce mutacije, povezane z različnimi zdravili in obravnavanje zgodovine posameznih bolnikov. Če so na voljo, odpornost testiranja je lahko primerno.